From: Adoption of new drugs by physicians: a survival analysis
Month since launching | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 3 | 6 | 12 | 24 | 36 | |||||||
n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | |
Cefditoren | 7 | 3.6 (4.2) | 26 | 2.3 (1.9) | 30 | 3.4 (2.8) | 32 | 3.3 (5.7) | 44 | 2.0 (2.2) | 51 | 2.6 (2.8) |
Duloxetine | 38 | 1.5 (0.9) | 67 | 2.0 (1.5) | 125 | 2.4 (2.0) | 172 | 3.5 (2.7) | 176 | 5.1 (3.8) | * | * |
Etoricoxib | 14 | 1.1 (0.4) | 32 | 1.6 (0.9) | 41 | 1.4 (0.6) | 44 | 1.5 (0.8) | 48 | 1.9 (1.3) | 124 | 3.1 (4.0) |
Ezetimibe | 31 | 2.0 (1.4) | 59 | 2.0 (1.5) | 94 | 2.3 (1.9) | 148 | 2.7 (2.5) | 200 | 4.0 (3.6) | 191 | 4.6 (3.8) |
Levocetirizine | 8 | 1.6 (0.9) | 9 | 1.6 (0.7) | 21 | 1.2 (0.4) | 75 | 2.2 (1.6) | 132 | 2.4 (1.7) | 158 | 3.0 (2.8) |
Olmesartan | 36 | 1.8 (1.0) | 49 | 2.2 (1.3) | 89 | 2.3 (1.7) | 131 | 3.4 (3.7) | 165 | 4.1 (4.8) | 182 | 4.7 (5.5) |
Pregabalin | 14 | 1.3 (0.5) | 31 | 1.7 (1.4) | 80 | 1.8 (1.0) | 137 | 2.3 (1.8) | 181 | 3.7 (2.7) | 198 | 5.1 (3.6) |
Tiotropium | 80 | 2.3 (1.6) | 127 | 2.9 (2.4) | 215 | 3.5 (2.6) | 244 | 5.9 (4.0) | 264 | 7.4 (4.9) | 264 | 8.5 (5.4) |